Charles Smith to Drug Synergism
This is a "connection" page, showing publications Charles Smith has written about Drug Synergism.
Connection Strength
0.315
-
Suppression of c-Myc and RRM2 expression in pancreatic cancer cells by the sphingosine kinase-2 inhibitor ABC294640. Oncotarget. 2016 Sep 13; 7(37):60181-60192.
Score: 0.132
-
Combined anticancer effects of sphingosine kinase inhibitors and sorafenib. Invest New Drugs. 2011 Dec; 29(6):1132-42.
Score: 0.085
-
Antitumor effect of the novel sphingosine kinase 2 inhibitor ABC294640 is enhanced by inhibition of autophagy and by sorafenib in human cholangiocarcinoma cells. Oncotarget. 2016 Apr 12; 7(15):20080-92.
Score: 0.032
-
Quinacrine sensitizes hepatocellular carcinoma cells to TRAIL and chemotherapeutic agents. Cancer Biol Ther. 2011 Aug 01; 12(3):229-38.
Score: 0.023
-
Quinacrine synergizes with 5-fluorouracil and other therapies in colorectal cancer. Cancer Biol Ther. 2011 Aug 01; 12(3):239-51.
Score: 0.023
-
Combining nanoliposomal ceramide with sorafenib synergistically inhibits melanoma and breast cancer cell survival to decrease tumor development. Clin Cancer Res. 2008 Jun 01; 14(11):3571-81.
Score: 0.019